Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
Institute of Biostructure and Bioimaging, National Council of Research, Naples, Italy
class="ui-helper-reset" aria-live="assertive">
1 Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy. Electronic address: cuocolo@unina.it.
2 Institute of Biostructure and Bioimaging, National Council of Research, Naples, Italy.
3 Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
References: Ba, F., Martin, W.R., Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice (2015) Parkinsonism & Related Disorders, 21, pp. 87-9
Badiavas, K., Molyvda, E., Iakovou, I., Tsolaki, M., Psarrakos, K., Karatzas, N., SPECT imaging evaluation in movement disorders: Far beyond visual assessment (2011) European Journal of Nuclear Medicine and Molecular Imaging, 38, pp. 764-773
Benamer, H.T., Patterson, J., Wyper, D.J., Hadley, D.M., Macphee, G.J., Grosset, D.G., Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake (2000) Movement Disorders, 15, pp. 692-698
Bischof Delaloye, A., Carrió, I., Cuocolo, A., Knapp, W., Gourtsoyiannis, N., McCall, I., White paper of the European Association of Nuclear Medicine (EANM) and the European Society of Radiology (ESR) on multimodality imaging (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34, pp. 1147-1151
Booij, J., Tissingh, G., Boer, G.J., Speelman, J.D., Stoof, J.C., Janssen, A.G., [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease (1997) Journal of Neurology, Neurosurgery, and Psychiatry., 62, pp. 133-140
Buck, A.K., Nekolla, S., Ziegler, S., Beer, A., Krause, B.J., Herrmann, K., SPECT/CT (2008) Journal of Nuclear Medicine, 49, pp. 1305-1319
Calvini, P., Rodriguez, G., Inguglia, F., Mignone, A., Guerra, U.P., Nobili, F., The basal ganglia matching tools package for striatal uptake semi-quantification: Description and validation (2007) European Journal of Nuclear Medicine and Molecular Imaging, 34, pp. 1240-1253
Catafau, A.M., Brain SPECT in clinical practice. Part I: Perfusion (2001) Journal of Nuclear Medicine, 42, pp. 259-271
Catafau, A.M., Tolosa, E., DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group, Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes (2004) Movement Disorders, 19, pp. 1175-1182
Colloby, S.J., Williams, E.D., Burn, D.J., Lloyd, J.J., McKeith, I.G., O'Brien, J.T., Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT (2005) European Journal of Nuclear Medicine and Molecular Imaging, 32, pp. 1176-1185
De Rosa, A., Pappatà, S., Pellegrino, T., De Leva, M.F., Maddaluno, G., Fiumara, G., Reduced cardiac 123I-metaiodobenzylguanidine uptake in patients with spinocerebellar ataxia type 2: A comparative study with Parkinson's disease (2013) European Journal of Nuclear Medicine and Molecular Imaging, 40, pp. 1914-1921
Druschky, A., Hilz, M.J., Platsch, G., Radespiel-Tröger, M., Druschky, K., Kuwert, T., Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT (2000) Journal of the Neurological Sciences, 175, pp. 3-12
Even-Sapir, E., Keidar, Z., Bar-Shalom, R., Hybrid imaging (SPECT/CT and PET/CT)-improving the diagnostic accuracy of functional/metabolic and anatomic imaging (2009) Seminars in Nuclear Medicine, 39, pp. 264-275
Fallahi, B., Esmaeili, A., Beiki, D., Oveisgharan, S., Noorollahi-Moghaddam, H., Erfani, M., Evaluation of (99m)Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders (2016) Annals of Nuclear Medicine, 30, pp. 153-162
Farid, K., Petras, S., Poullias, X., Caillat-Vigneron, N., Clinical impact of nonuniform CT-based attenuation correction in brain perfusion SPECT/CT using (99m)Tc-ECD (2014) Clinical Nuclear Medicine, 39, pp. 343-345
Giorgio, S.M., Caprio, M.G., Galante, F., Russo, G., Romano, A., Vergara, E., Clinical value of perfusion abnormalities of brain on technetium-99m HMPAO single-photon emission computed tomography in children with Sydenham chorea (2017) Journal of Child Neurology, 32, pp. 316-321
Habraken, J.B., Booij, J., Slomka, P., Sokole, E.B., van Royen, E.A., Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm (1999) Journal of Nuclear Medicine, 40, pp. 1091-1097
Hayashi, M., Deguchi, J., Utsunomiya, K., Yamada, M., Komori, T., Takeuchi, M., Comparison of methods of attenuation and scatter correction in brain perfusion SPECT (2005) Journal of Nuclear Medicine Technology, 33 (4), pp. 224-229
Hellwig, S., Kreft, A., Amtage, F., Tüscher, O., Winz, O.H., Hellwig, B., 123I-iodobenzamide SPECT is not an independent predictor of dopaminergic responsiveness in patients with suspected atypical parkinsonian syndromes (2013) Journal of Nuclear Medicine, 54, pp. 2081-2086
Huang, W.S., Chiang, Y.H., Lin, J.C., Chou, Y.H., Cheng, C.Y., Liu, R.S., Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients (2003) Journal of Nuclear Medicine, 44, pp. 999-1005
Huang, W.S., Lee, M.S., Lin, J.C., Chen, C.Y., Yang, Y.W., Lin, S.Z., Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease (2004) European Journal of Nuclear Medicine and Molecular Imaging, 31, pp. 155-161
Im, J.H., Chung, S.J., Kim, J.S., Lee, M.C., Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: Analysis with [(123)I]IPT single photon emission computed tomography (2006) Journal of the Neurological Sciences, 244, pp. 103-109
Kashihara, K., Ohno, M., Kawada, S., Okumura, Y., Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies (2006) Journal of Nuclear Medicine, 47, pp. 1099-1101
Kato, H., Shimosegawa, E., Fujino, K., Hatazawa, J., CT-based attenuation correction in brain SPECT/CT can improve the lesion detectability of voxel-based statistical analyses (2016) PLoS One, 11
Kim, Y.D., Jeong, H.S., Song, I.U., Chung, Y.A., Namgung, E., Kim, Y.D., Brain perfusion alterations in depressed patients with Parkinson's disease (2016) Annals of Nuclear Medicine, 30, pp. 731-737
Koch, W., Hamann, C., Welsch, J., Pöpperl, G., Radau, P.E., Tatsch, K., Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? (2005) Journal of Nuclear Medicine, 46, pp. 1804-1811
Larobina, M., Nappi, C., Gaudieri, V., Cuocolo, A., Instrumentation (2016) PET-CT and PET-MRI in neurology, SWOT analysis applied to hybrid imaging, pp. 13-22. , A. Ciarmiello L. Mansi Springer
Liu, Z.Y., Liu, F.T., Zuo, C.T., Koprich, J.B., Wang, J., Update on molecular imaging in Parkinson's disease (2018) Neuroscience Bulletin, 34, pp. 330-340
Lizarraga, K.J., Gorgulho, A., Chen, W., De Salles, A.A., Molecular imaging of movement disorders (2016) World Journal of Radiology, 8, pp. 226-239
Lu, F.M., Yuan, Z., PET/SPECT molecular imaging in clinical neuroscience: Recent advances in the investigation of CNS diseases (2015) Quantitative Imaging in Medicine and Surgery, 5, pp. 433-447
Mascalchi, M., Vella, A., Ceravolo, R., Movement disorders: Role of imaging in diagnosis (2012) Journal of Magnetic Resonance Imaging, 35, pp. 239-256
Matsui, H., Udaka, F., Miyoshi, T., Hara, N., Tamura, A., Oda, M., Brain perfusion differences between Parkinson's disease and multiple system atrophy with predominant parkinsonian features (2005) Parkinsonism & Related Disorders, 11, pp. 227-232
Morano, G.N., Seibyl, J.P., Technical overview of brain SPECT imaging: Improving acquisition and processing of data (2003) Journal of Nuclear Medicine Technology, 31, pp. 191-195
Nuvoli, S., Spanu, A., Piras, M.R., Nieddu, A., Mulas, A., Rocchitta, G., 123I-ioflupane brain SPECT and 123I-MIBG cardiac planar scintigraphy combined use in uncertain parkinsonian disorders (2017) Medicine (Baltimore), 96
Pappatà, S., Salvatore, E., Postiglione, A., In vivo imaging of neurotransmission and brain receptors in dementia (2008) Journal of Neuroimaging, 18, pp. 111-124
Politis, M., Neuroimaging in Parkinson disease: From research setting to clinical practice (2014) Nature Reviews. Neurology, 10, pp. 708-722
Radau, P.E., Linke, R., Slomka, P.J., Tatsch, K., Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism (2000) Journal of Nuclear Medicine, 41, pp. 220-227
Saeed, U., Compagnone, J., Aviv, R.I., Strafella, A.P., Black, S.E., Lang, A.E., Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: Current and emerging concepts (2017) Translational Neurodegeneration, 28, pp. 6-8
Salvatore, M., Nappi, C., Cuocolo, A., PET/MR in children (2016) Clinical nuclear medicine in pediatrics, pp. 19-28. , L. Mansi E. Lopci V. Cuccurullo A. Chiti Springer Cham
Scherfler, C., Seppi, K., Donnemiller, E., Goebel, G., Brenneis, C., Virgolini, I., Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease (2005) Brain, 128, pp. 1605-1612
Schwarz, J., Tatsch, K., Gasser, T., Arnold, G., Pogarell, O., Künig, G., 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism (1998) Movement Disorders, 13, pp. 16-19
Shimizu, S., Hirose, D., Namioka, N., Kanetaka, H., Hirao, K., Hatanaka, H., Correlation between clinical symptoms and striatal DAT uptake in patients with DLB (2017) Annals of Nuclear Medicine, 31, pp. 390-398
Soricelli, A., Postiglione, A., Cuocolo, A., De Chiara, S., Ruocco, A., Brunetti, A., Effect of adenosine on cerebral blood flow as evaluated by single-photon emission computed tomography in normal subjects and in patients with occlusive carotid disease. A comparison with acetazolamide (1995) Stroke, 26, pp. 1572-1576
Stam, M.K., Verwer, E.E., Booij, J., Adriaanse, S.M., de Bruin, C.M., de Wit, T.C., Performance evaluation of a novel brain-dedicated SPECT system (2018) European Journal of Nuclear Medicine and Molecular Imaging Physics, 5, p. 4
Suwijn, S.R., van Boheemen, C.J., de Haan, R.J., Tissingh, G., Booij, J., de Bie, R.M., The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: A systematic review (2015) European Journal of Nuclear Medicine and Molecular Imaging Research, 17, pp. 5-12
Takaya, S., Sawamoto, N., Okada, T., Okubo, G., Nishida, S., Togashi, K., Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT (2018) Parkinsonism & Related Disorders, 47, pp. 15-21
Van Laere, K., Santens, P., Bosman, T., De Reuck, J., Mortelmans, L., Dierckx, R., Statistical parametric mapping of (99m)Tc-ECD SPECT in idiopathic Parkinson's disease and multiple system atrophy with predominant parkinsonian features: Correlation with clinical parameters (2004) Journal of Nuclear Medicine, 45, pp. 933-942
Varrone, A., Marek, K.L., Jennings, D., Innis, R.B., Seibyl, J.P., [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy (2001) Movement Disorders, 16, pp. 1023-1032
Varrone, A., Pappata, S., Quarantelli, M., Movement disorders: Focus on Parkinson's disease and related disorders (2016) PET-CT and PET-MRI in neurology, SWOT analysis applied to hybrid imaging, pp. 103-125. , A. Ciarmiello L. Mansi Springer
Wang, L., Zhang, Q., Li, H., Zhang, H., SPECT molecular imaging in Parkinson's disease (2012) Journal of Biomedicine and Biotechnology, 2012, p. 412486. , Epub 2012 Mar 24. Review
Weng, Y.H., Yen, T.C., Chen, M.C., Kao, P.F., Tzen, K.Y., Chen, R.S., Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects (2004) Journal of Nuclear Medicine, 45, pp. 393-401
Winogrodzka, A., Bergmans, P., Booij, J., van Royen, E.A., Stoof, J.C., Wolters, E.C., [(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease (2003) Journal of Neurology, Neurosurgery and Psychiatry, 74, pp. 294-298
Zhu, L., Ploessl, K., Kung, F.K., PET/SPECT imaging agents for neurodegenerative diseases (2014) Chemical Society Reviews, 43 (19), pp. 6683-6691
Ziebell, M., Andersen, B.B., Thomsen, G., Pinborg, L.H., Karlsborg, M., Hasselbalch, S., Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms (2012) European Journal of Nuclear Medicine and Molecular Imaging, 39, pp. 242-250
Advances in SPECT Methodology
The emerging role of molecular imaging has made possible to evaluate and
quantify biochemical changes of molecular targets in specific
neurochemical systems involved in movement disorders, providing
neurochemical information of clinical changes before the pathological
features occurred. In detail, radionuclides imaging techniques are
frequently used for the in vivo study of neurotransmitter and receptor
function, alterations in cerebral blood flow and metabolic activity,
abnormal protein deposition, and inflammation, with a central role in
molecular imaging for preclinical and clinical studies. The present
chapter represents an overview of main use of single-photon emission
computed tomography (SPECT) in movement disorders, with a focal
attention on specific radiotracers used, recent advances in SPECT
technology and reconstruction algorithm and added specific value of
semiquantitative methods for images analysis. Finally, a brief paragraph
is dedicated to description of SPECT/CT devices and advantages of using
hybrid technology.